trending Market Intelligence /marketintelligence/en/news-insights/trending/fj75exfaj05piukgvukt_a2 content esgSubNav
In This List

Curis blood cancer drug secures US FDA fast-track designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Curis blood cancer drug secures US FDA fast-track designation

The U.S. Food and Drug Administration granted Curis Inc.'s medicine fimepinostat fast-track designation to treat patients with a certain type of blood cancer.

The Lexington, Mass.-based biotechnology company is developing the drug, also known as CUDC-907, to treat diffuse large B-cell lymphoma patients who have been resistant to treatment or whose cancer returned following two previous therapies.

DLBCL is an aggressive type of non-Hodgkin lymphoma that develops from the B-cells in the lymphatic system.

The U.S. FDA's fast-track process is designed to facilitate development and expedite review of drugs used to treat serious conditions and fill an unmet medical need.

The status also provides eligibility for accelerated approval and priority review, given the appropriate criteria are met.